A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
08/2011
08/04/2011	US20110189173 PHOSPHORYLATED C-ErbB2 AS A SUPERIOR PREDICTIVE THERANOSTIC MARKER FOR THE DIAGNOSIS AND TREATMENT OF CANCER
08/04/2011	US20110189172 Methods for the treatment of rheumatoid arthritis
08/04/2011	US20110189171 Recombinant antibodies for treatment of respiratory syncytial virus infections
08/04/2011	US20110189170 Chimeric Anti-VEGF-D Antibodies and Humanized Anti-VEGF-D Antibodies and Methods of Using the Same
08/04/2011	US20110189169 Combination of hgf inhibitor and pten agonist to treat cancer
08/04/2011	US20110189168 Antibody-induced apoptosis
08/04/2011	US20110189167 Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
08/04/2011	US20110189166 Methods of treating hemorheologic abnormalities in mammals
08/04/2011	US20110189165 Method of identifying disease risk factors
08/04/2011	US20110189164 Peptide Stabilizer Compounds and Screening Method
08/04/2011	US20110189139 Hematopoietic Cell E-Selectin/L-Selectin Ligand Glycosylated CD44 Polypeptide
08/04/2011	US20110189130 Dihydropyrazolopyrimidinone derivatives
08/04/2011	US20110189129 Hepatitis c virus inhibitors
08/04/2011	US20110189127 Tricyclic indole derivatives and methods of use thereof
08/04/2011	US20110189123 Mammalian cx3c chemokine antibodies
08/04/2011	US20110189120 Aegyptin and uses thereof
08/04/2011	US20110189093 Prostate specific membrane antigen antibodies and antigen binding fragments
08/04/2011	US20110189087 TMPRSS4-Specific Human Antibody
08/04/2011	US20110189086 Diagnostic Method for Atherosclerosis
08/04/2011	US20110189085 Antibody Therapy
08/04/2011	US20110189084 Method for Treating Liver Disorders with Receptor Associated Protein (RAP) Peptide-Fucosidase Inhibitor Conjugates
08/04/2011	US20110189083 Dock-and-Lock (DNL) Vaccines for Cancer Therapy
08/04/2011	US20110189082 Human gm-csf antigen binding proteins
08/04/2011	CA2825952A1 Influenza virus compositions and methods for universal vaccines
08/04/2011	CA2825861A1 Conjugates utilizing platform technology for stimulating immune response
08/04/2011	CA2825282A1 Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
08/04/2011	CA2788527A1 Pharmaceutical composition for osteoarthritis treatment or prevention and manufacturing method therefor
08/04/2011	CA2787615A1 Methods of treating diabetes with dll4 antagonists
08/04/2011	CA2787394A1 Methods of treating autoimmune diseases with dll4 antagonists
08/04/2011	CA2787070A1 Cd127 binding proteins
08/04/2011	CA2786969A1 Modified tuberculosis antigens
08/04/2011	CA2786817A1 Extracellular ifi16 as therapeutic agents
08/04/2011	CA2786333A1 Vaccinia virus mutants containing the major genomic deletions of mva
08/03/2011	EP2351840A1 Polypeptides involved in immune response
08/03/2011	EP2351838A1 Crosslinking agonistic antibodies
08/03/2011	EP2351835A1 Method for producing purified influenza virus antigen
08/03/2011	EP2351834A2 Production of biologically active proteins
08/03/2011	EP2351832A1 Composition for inducing th2 cell, therapeutic composition for th2-type disease, and use of same
08/03/2011	EP2351826A1 Kit for preparation of antigen-specific cytotoxic t lymphocyte
08/03/2011	EP2351777A1 Anti-muc1 antibody
08/03/2011	EP2351774A1 Polypeptides from non-typeable haemophilus influenzae
08/03/2011	EP2351773A1 Polypeptides from non-typeable haemophilus influenzae
08/03/2011	EP2351771A1 Immunosuppressive peptide
08/03/2011	EP2351770A1 Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
08/03/2011	EP2351769A2 Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom
08/03/2011	EP2351768A1 HBV core antigen particles with multiple immunogenic components attached via peptide ligands
08/03/2011	EP2351767A2 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
08/03/2011	EP2351599A1 Method for producing dendritic cells
08/03/2011	EP2351584A1 Novel anti-IL 13 antibodies and uses thereof
08/03/2011	EP2351583A1 Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis
08/03/2011	EP2351582A1 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
08/03/2011	EP2351581A1 A vaccine composition against foot-and-mouth disease and the preparation method thereof
08/03/2011	EP2351580A1 Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof. therapeutic uses thereof
08/03/2011	EP2351579A1 Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
08/03/2011	EP2351578A1 Process for manufacturing vaccines
08/03/2011	EP2351577A1 Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
08/03/2011	EP2351576A1 Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
08/03/2011	EP2351483A1 Prevention and treatment of blood coagulation-related diseases
08/03/2011	EP2350649A1 Stable antibody compositions and methods for stabilizing same
08/03/2011	EP2350641A1 Method of treatment
08/03/2011	EP2350318A1 Methods, compositions, and kits for diagnosing, monitoring, and treating disease
08/03/2011	EP2350305A1 Combination treatments comprising protease binding proteins for inflammatory disorders
08/03/2011	EP2350304A2 Toll-like receptor 3 antagonists
08/03/2011	EP2350282A1 Increased expression of specific antigens
08/03/2011	EP2350270A2 Human ebola virus species and compositions and methods thereof
08/03/2011	EP2350264A2 Treatment of chronic inflammatory respiratory disorders
08/03/2011	EP2349520A1 Purification method
08/03/2011	EP2349339A2 Sustained drug delivery system
08/03/2011	EP2349333A1 Mimotopes of hiv env
08/03/2011	EP2349332A2 Methods and compositions for regulating iron homeostasis by modulation bmp-6
08/03/2011	EP2349331A2 Humanized anti-il-6 antibodies
08/03/2011	EP2349330A1 Methods for mediating fibrotic response
08/03/2011	EP2349329A1 Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
08/03/2011	EP2349328A1 Methods for the treatment of cancer
08/03/2011	EP2349327A2 Directed engagement of activating fc receptors
08/03/2011	EP2349315A1 Regulation of lymphocytes and uses therefor
08/03/2011	EP2349291A2 Agonists of toll-like receptor 5 for the treatment of graft-versus-host disease
08/03/2011	EP2349233A1 Use of scyllo-inositols for the treatment of macular degeneration-related disorders
08/03/2011	EP2349224A1 Orally administrable immunostimulant product for aquaculture
08/03/2011	EP2118292B1 Papillomavirus e2 polypeptide used for vaccination
08/03/2011	EP1860119B1 ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME
08/03/2011	EP1692265B1 Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins
08/03/2011	EP1688488B1 Bispecific antibody substituting for factor viii
08/03/2011	EP1688432B1 Igm high concentration stabilized solution
08/03/2011	EP1631314B1 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
08/03/2011	EP1575483B1 Attenuated gram negative bacteria
08/03/2011	EP1534753B1 Peg positional isomer of an anti-tnfalpha antibody (cdp870)
08/03/2011	EP1391202B1 Liquid drug preparations
08/03/2011	EP1317282B1 Vectors for molecule delivery to cd11b expressing cells
08/03/2011	EP1232168B1 Synthetic lipid-a analogs and uses thereof
08/03/2011	EP1078092B1 Expression vectors for stimulating an immune response and methods of using the same
08/03/2011	EP0784631B1 Method of producing a partial orf2 protein of hepatitis e virus
08/03/2011	CN1901937B Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
08/03/2011	CN102143978A Anti- P2X7 peptides and epitopes
08/03/2011	CN102143977A Multispecific antibodies
08/03/2011	CN102143976A Stable and soluble antibodies inhibiting VEGF
08/03/2011	CN102143975A Therapeutic use of specific ligand in MSRV associated diseases
08/03/2011	CN102143974A Human cytomegalovirus neutralising antibodies and use thereof
08/03/2011	CN102143973A MSP-1 protein preparations from plasmodium
08/03/2011	CN102143760A Prostaglandin E2 binding proteins and uses thereof

1 ... 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 ... 1823